Today, I review, link to, and embed Doctor Eye Health‘s “GLP 1 Blindness Risk | Should You Be Worried?”
All that follows is from the above resource.
GLP 1 Blindness Risk | Should You Be Worried?
Mar 10, 2026
Chapters: 0:00 Ozempic and Blindness 1:41 What are the side effects? 2:48 How risky are GLP 1 meds? 4:43 What does the science say? 6:20 Who is most at risk? 8:17 Final thoughts
The GLP 1 Blindness risk is real. GLP-1 medications like Ozempic, Wegovy, and others are now being discussed in legal cases related to vision loss and blindness. But what does the science actually say about the risk? In this video, we break down the latest research on GLP 1 medications and eye health, including the potential link to non-arteritic anterior ischemic optic neuropathy (NAION) – a rare type of optic nerve stroke that can cause sudden vision loss. GLP-1 drugs are widely used for type 2 diabetes and weight loss, and while they offer powerful metabolic and cardiovascular benefits, researchers are continuing to investigate potential side effects, including rare vision complications. In this video, you’ll learn: • What NAION (eye stroke) is and how it causes vision loss • The estimated risk of vision loss linked to GLP-1 medications • Why the absolute risk remains very low • Other eye conditions that may be affected, including diabetic retinopathy and macular degeneration • Who may be at higher risk of developing optic nerve complications • Why a baseline comprehensive eye exam is recommended when starting GLP-1 medications • Important questions to ask your eye doctor If you are currently taking a GLP-1 medication — or considering one — this video will help you understand the real risks, symptoms to watch for, and how to protect your vision. 👍 If you enjoy learning about eye health and vision science, subscribe for weekly videos to help you protect your sight. Resources & Research Mentioned: https://www.aoa.org/AOA/Documents/Pra… https://jamanetwork.com/journals/jama… https://jamanetwork.com/journals/jama… https://pubmed.ncbi.nlm.nih.gov/40631… https://www.reuters.com/legal/governm… https://www.nejm.org/doi/10.1056/NEJM…
